Genetic Epidemiology

OFFICIAL JOURNAL
INTERNATIONAL GENETIC
EPIDEMIOLOGY SOCIETY
www.geneticepi.org

WILEY

Check for updates

RESEARCH ARTICLE

Ordered multinomial regression for genetic association analysis of ordinal phenotypes at Biobank scale

Christopher A. German[1] | Janet S. Sinsheimer[1,2,3] | Yann C. Klimentidis[4] | Hua Zhou[1] | Jin J. Zhou[4]

[1]Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, California

[2]Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California

[3]Department of Computational Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

[4]Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona

Correspondence
Jin J. Zhou, Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ.
Email: jzhou@email.arizona.edu

Abstract
Logistic regression is the primary analysis tool for binary traits in genome-wide association studies (GWAS). Multinomial regression extends logistic regression to multiple categories. However, many phenotypes more naturally take ordered, discrete values. Examples include (a) subtypes defined from multiple sources of clinical information and (b) derived phenotypes generated by specific phenotyping algorithms for electronic health records (EHR). GWAS of ordinal traits have been problematic. Dichotomizing can lead to a range of arbitrary cutoff values, generating inconsistent, hard to interpret results. Using multinomial regression ignores trait value hierarchy and potentially loses power. Treating ordinal data as quantitative can lead to misleading inference. To address these issues, we analyze ordinal traits with an ordered, multinomial model. This approach increases power and leads to more interpretable results. We derive efficient algorithms for computing test statistics, making ordinal trait GWAS computationally practical for Biobank scale data. Our method is available as a Julia package *OrdinalGWAS.jl*. Application to a COPDGene study confirms previously found signals based on binary case–control status, but with more significance. Additionally, we demonstrate the capability of our package to run on UK Biobank data by analyzing hypertension as an ordinal trait.

KEYWORDS
electronic health record, genome-wide association study, ordered multinomial regression

1 | INTRODUCTION

Genome-wide association studies (GWAS) have enjoyed many successes and uncovered many clues to the genetic etiology of common diseases (Visscher et al., 2017). Large international consortia are now undertaking collaborative meta-analyses of the results of separate GWAS, utilizing effective sample sizes of tens of thousands of

individuals for discovery and replication of increasingly modest genetic effects. Besides larger sample sizes, richer information is available. For instance, UK Biobank (Sudlow et al., 2015) and the Million Veteran Project (MVP; Gaziano et al., 2016) contain electronic health records (EHR) of individuals along with their genomic information. Big data bring both blessings and curses. One particular challenge is to properly define phenotypes that are both meaningful and powerful for genetic association testing. Both classical genetic epidemiology studies and EHR can possess hundreds of clinically relevant variables that are associated with the underlying phenotypes of interest. In contrast to directly available phenotypes, derived phenotypes are generated by potentially complicated phenotyping algorithms. Below are two examples.

COPD: For classifying chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has proposed a simple algorithm to classify cases into Stages 1–4, ranging from least severe to most severe (Vestbo et al., 2013). Three quantitative measures—forced expiratory volume (FEV1), forced vital capacity (FVC), and forced predicted expiratory volume (FEV1-predicted)—are used to define the GOLD categories. Under this classification individuals with an FEV1/FVC ratio that is <0.70 are considered cases with severity increasing as FEV1-predicted value decreases. Individuals with an FEV1/FVC ratio that is at least 0.70 and an FEV1-predicted that is at least 80% are considered unaffected. Individuals with a FEV1/FVC ratio of at least 0.70, but have a low FEV1-predicted value (<80%), are categorized into a GOLD unclassifiable category (Wan et al., 2011). These individuals are typically analyzed separately:

Not a case: FEV1/FVC ≥ 0.7 and FEV1-predicted ≥80%;
GOLD unclassifiable: FEV1/FVC ≥ 0.7 and FEV1-predicted <80%;
GOLD Stage 1 (mild): FEV1/FVC <0.7 and FEV1-predicted ≥80%;
GOLD Stage 2 (moderate): FEV1/FVC <0.7 and 50%≤ FEV1-predicted <80%;
GOLD Stage 3 (severe): FEV1/FVC <0.7 and 30%≤ FEV1-predicted <50%;
GOLD Stage 4 (very severe): FEV1/FVC <0.7 and FEV1-predicted <30%.

Figure 1 shows the correspondence between GOLD values and FEV1-predicted and FVC in the COPD-Gene study (Regan et al., 2010). One can carry out association testing of the bivariate trait (FEV1, FVC) or (FEV1/FVC, FVC). However multivariate modeling


FIGURE 1 GOLD stage values plotted with FVC and FEV1-predicted values. FEV1, forced expiratory volume; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease

requires more parameters and the single nucleotide polymorphism (SNP) effects may not correlate with GOLD stages, leading to hard to interpret results. Current GWAS were performed as a case–control study by treating individuals in the *not a case* category as controls and individuals with GOLD Stages 2–4 as cases (Lutz et al., 2015). This approach, although statistically permissible, is inefficient because it assumes that the odds of disease are the same in Groups 2–4 and omits Group 1 entirely.

EHR-based phenotyping: Recently EHRs have emerged as a major data source for clinical and health services research. It has been a common practice to extract a patient's disease status by automated phenotyping algorithms applied to EHR. Compared with the COPD example, the output from a phenotyping algorithm can have more categories as the underlying information is more complex. For example, Eastwood et al. (2016) developed an EHR algorithm to classify Type 2 diabetes (T2D) prevalence for the UK Biobank data, a Biobank study that has phenotypic and genotypic data on over 500,000 people. On the basis of several different features in the EHR, including diabetes diagnostic codes, diabetes medication, hyperglycemia in blood results defined by HbA_{1c} and fasting glucose levels, and the presence of diabetes process of care codes, the algorithm categorizes individuals into different categories that relate to how likely they are to have diabetes. The algorithm classifies individuals into categories *diabetes unlikely*, *possible T2D*, *probable T2D*, and *probable type 1 diabetes*. Excluding those diagnosed with *probable type 1 diabetes*, ordinal phenotype labels are produced.

In both cases, the derived phenotypes take discrete, ordinal values. GOLD status clearly correlates with

lung function. Labels from the EHR phenotyping algorithm for T2D indicate a hierarchy in the uncertainty in disease diagnosis. Often, the analysis strategy reduces ordinal values to two categories and resorts to logistic regression for case–control studies. COPDGene study reports GWAS results using *not a case* as controls and *GOLD Stages 2–4* as cases (Lutz et al., 2015). In the T2D phenotyping algorithm (Eastwood et al., 2016), there are three possible case groups. Similarly the algorithm for T2D control can also have multiple categories leading to at least three possible case–control cohorts. This freedom in the choice of case and control labels necessitates multiple analyses of the same data. Besides needing to pay a price for more testing, inconsistent findings from these correlated analyses can be difficult to reconcile. To address this issue, we propose using the ordered multinomial regression in association studies of ordinal traits. Taking ordinality into account can significantly boost the power in association studies.

Ordinal categorical data analysis has been a well-studied area in statistics (Agresti, 2010). However it has attracted relatively less attention in genetic association studies. Morris et al. (2010) use multinomial regression for GWAS on multicategory traits. However, ignoring order information may lead decreased power. Several authors (O'Reilly et al., 2012; Wang, 2014) treat genotypes as ordinal responses and regress genotype dosage on multiple phenotypes. This retrospective approach ignores the ordinal feature of the phenotypes, is not easily generalized to multilocus models and gene-by-environmental interactions, and the results can be difficult to interpret. Treating the ordinal values as a univariate quantitative trait is also commonly used in practice. In the binary case, this strategy can be justified as a first-order approximation to logistic regression (Agresti, 2018). For multiple categories, unequal distances between the categories can violate the assumptions of linear regression and lead to incorrect inference. For instance the distance between mild pain and moderate pain can be different from that between moderate pain and intense pain. However, the ordering is clear.

In this article we make several substantial contributions to GWAS for ordinal phenotypes. First, we systematically investigate the performance (Type I error and power) of the ordered multinomial model in comparison with linear regression (treating ordinal traits as continuous traits), logistic regression (by dichotomizing ordinal traits), and multinomial regression (ignoring ordinality), in a variety of genetically plausible scenarios. Second, we derive an efficient testing strategy that is scalable to GWAS on Biobank

data. Our test applies to a single SNP, SNP-sets, or SNP–environment interactions. Third, we implement the methodology in the open source, high-performance language Julia, which is available for free at https://github.com/OpenMendel/Ordinal-GWAS.jl.

2 | METHODS

2.1 | Association mapping with ordered multinomial models

We assume that trait Y takes ordinal values $j \in \{1, ..., J\}$. For example, in the COPD example $J = 5$ (excluding the unclassifiable category). Denote the cumulative probabilities of the trait value Y_i of ith individual by

$$\alpha_{ij} = \mathbb{P}(Y_i \leq j).$$

Since $\alpha_{iJ} = 1$, we only need to model $J - 1$ cumulative probabilities. The ordered multinomial model (Agresti, 2010) links α_{ij} to covariates $\boldsymbol{x}_i$ by

$$g(\alpha_{ij}) = \theta_j - \boldsymbol{x}_i^T \boldsymbol{\beta}, \quad j = 1, ..., J - 1,$$

where g is a strictly increasing link function, the intercepts θ_j satisfy the monotonicity constraint $\theta_1 \leq \theta_2 \leq \cdots \leq \theta_{J-1}$, and $\boldsymbol{\beta}$ are the regression coefficients for covariates. This assumes that regression coefficients $\boldsymbol{\beta}$ have the same effects on each of the response categories but each category has its own intercept. The maximum likelihood estimate (MLE) of parameters $\boldsymbol{\theta} = (\theta_1, ..., \theta_{J-1})$ and $\boldsymbol{\beta}$ is the maximizer of the sample loglikelihood. Different choices for the link function g lead to the classical proportional odds model (logit link), the ordered Probit model (Probit link), or the proportional hazards model (cloglog link). In practice, we choose the link function based on data according to goodness-of-fit measures, such as the deviance ($-2 \times$ loglikelihood) at respective MLEs Table 1).

Under the logit link, the effect size can be interpreted as the expected change of the response variable in the

TABLE 1 Commonly used ordered multinomial models

Link	g	Model
Logit	$g(\alpha) = \alpha/(1 - \alpha)$	Proportional odds model
Probit	$g(\alpha) = \Phi^{-1}(\alpha)$	Ordered Probit model
Cloglog	$g(\alpha) = \log(-\log(1 - \alpha))$	Proportional hazard model

ordered-log odds scale for a one unit increase in the predictor. For example, an effect size of 0.25 gives an odds ratio of 1.28, which can be interpreted as the odds of being in a higher grouping (e.g., severe and most severe) is 1.28 times greater than being in a lower grouping (e.g., mild and moderate). Other link functions yield less interpretable effect sizes.

Suppose $x \in \mathbb{R}^p$ contains p nongenetic covariates, such as age, sex, smoking status, and ethnic ancestry proxies (e.g., first few principal components of the genotype matrix), and $G \in \mathbb{R}^q$ contains the genetic information to be tested. For a single SNP, G is the scalar genotype dosage. For an SNP-set, G is the genotype dosage vector of q SNPs. To test gene-by-environment ($G \times E$), including gene-by-drug interactions, G contains both genotype dosage and its interaction with other covariates. The likelihood ratio test (LRT) compares the loglikelihood at the MLE of the full model $g(\alpha_{ij}) = \theta_j - x^T\beta - G^T\gamma$ to that at the null model $g(\alpha_{ij}) = \theta_j - x^T\beta$. LRT enjoys higher power than the score test and Wald test at small to moderate sample sizes and also outputs effect sizes. However, in the GWAS setting, the full model needs to be refitted at each single SNP or SNP-set, which becomes computationally challenging for Biobank scale data. In contrast, the score test only requires fitting the null model once for the entire GWAS. Testing each SNP only involves forming the score test statistic and is computationally cheap. A practical strategy is to perform a score test on all SNPs first and then only the top SNPs with the most significant score test p values are reanalyzed by the slightly more powerful, but much slower, LRT. When sample size (e.g., $n = 2,500$ or greater) is reasonable, score test provides comparable power with LRT (Supporting Information Section S.6 and Figure S9).

2.2 | Score tests for individual SNPs, SNP-set, or $G \times E$

Let μ denote the inverse link function g^{-1}. The loglikelihood of a single observation (y_i, x_i) is

$$
\begin{aligned}
\ell_i(\theta, \beta) &= \ln(\alpha_{ij} - \alpha_{i,j-1}) \\
&= \ln\left[\mu\left(\theta_{y_i} - x_i^T\beta\right) - \mu\left(\theta_{y_i-1} - x_i^T\beta\right)\right] \\
&= \ln p_{iy_i}
\end{aligned}
$$

with score (gradient)

$$
\frac{\partial}{\partial\theta_j}\ell_i(\theta, \beta) = \begin{cases} p_{ij}^{-1}\mu'\left(\theta_j - x_i^T\beta\right), & y_i = j, \\ -p_{i,j+1}^{-1}\mu'\left(\theta_j - x_i^T\beta\right), & y_i = j+1, \\ 0, & \text{otherwise,} \end{cases}
$$

$$
\nabla_\beta \ell_i(\theta, \beta) = -p_{iy_i}^{-1}\left[\mu'\left(\theta_{y_i} - x_i^T\beta\right) - \mu'\left(\theta_{y_i-1} - x_i^T\beta\right)\right]x_i
$$

and Hessian

$$
\frac{\partial^2}{\partial\theta_j\partial\theta_{j'}}\ell_i(\theta, \beta)
$$

$$
= \begin{cases} p_{ij}^{-1}\mu''\left(\theta_j - x_i^T\beta\right) & y_i = j = j', \\ \quad - \left[p_{ij}^{-1}\mu'\left(\theta_j - x_i^T\beta\right)\right]^2, & \\ -p_{i,j+1}^{-1}\mu''\left(\theta_j - x_i^T\beta\right) & y_i = j+1 = j'+1, \\ \quad - \left[p_{i,j+1}^{-1}\mu'\left(\theta_j - x_i^T\beta\right)\right]^2, & \\ p_{ij}^{-2}\mu'\left(\theta_j - x_i^T\beta\right)\mu'\left(\theta_{j-1} - x_i^T\beta\right), & y_i = j = j'+1, \\ p_{i,j+1}^{-2}\mu'\left(\theta_{j+1} - x_i^T\beta\right)\mu'\left(\theta_j \right. & y_i = j' = j+1, \\ \quad \left. - x_i^T\beta\right), & \\ 0, & \text{otherwise,} \end{cases}
$$

$$
\nabla_\beta\frac{\partial}{\partial\theta_j}\ell_i(\theta, \beta)
$$

$$
= \begin{cases} \left\{-p_{ij}^{-1}\mu''\left(\theta_j - x_i^T\beta\right) + p_{ij}^{-2}\left[\mu'\left(\theta_j - x_i^T\beta\right)\right.\right. & y_i = j, \\ \quad \left.\left. - \mu'\left(\theta_{j-1} - x_i^T\beta\right)\right]\mu'\left(\theta_j - x_i^T\beta\right)\right\}x_i, & \\ \left\{p_{i,j+1}^{-1}\mu''\left(\theta_j - x_i^T\beta\right)\right. & y_i = j+1, \\ \quad - p_{i,j+1}^{-2}\left[\mu'\left(\theta_{j+1} - x_i^T\beta\right)\right. & \\ \quad \left. - \mu'\left(\theta_j - x_i^T\beta\right)\right]\mu'\left(\theta_j - x_i^T\beta\right)\right\}x_i, & \\ 0, & \text{otherwise,} \end{cases}
$$

$$
\nabla_\beta^2\ell_i(\theta, \beta) = \left\{p_{iy_i}^{-1}\left[\mu''\left(\theta_{y_i} - x_i^T\beta\right) - \mu''\left(\theta_{y_i-1} - x_i^T\beta\right)\right]\right.
$$

$$
\left. - p_{iy_i}^{-2}\left[\mu'\left(\theta_{y_i} - x_i^T\beta\right) - \mu'\left(\theta_{y_i-1} - x_i^T\beta\right)\right]^2\right\}x_ix_i^T.
$$

The Fisher (expected) information matrix (FIM) has entries

$$\mathbb{E}\left[-\frac{\partial^2}{\partial\theta_j\partial\theta_{j'}}\ell_i(\theta,\boldsymbol{\beta})\right]$$

$$= \begin{cases} \left(p_{ij}^{-1}+p_{i,j+1}^{-1}\right)\left[\mu'\left(\theta_j-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)\right]^2, & j=j', \\ -p_{ij}^{-1}\mu'\left(\theta_j-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)\mu'\left(\theta_{j-1}-\boldsymbol{x}_i^T\boldsymbol{\beta}\right), & j=j'+1, \\ -p_{i,j+1}^{-1}\mu'\left(\theta_j-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)\mu'\left(\theta_{j+1} & j'=j+1, \\ \quad -\boldsymbol{x}_i^T\boldsymbol{\beta}\right), & \\ 0, & \text{otherwise,} \end{cases}$$

$$\mathbb{E}\left[-\nabla_{\boldsymbol{\beta}}\frac{\partial}{\partial\theta_j}\ell_i(\theta,\boldsymbol{\beta})\right]$$

$$= \left[p_{ij}^{-1}\mu'\left(\theta_{j-1}-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)-\left(p_{ij}^{-1}+p_{i,j+1}^{-1}\right)\mu'\left(\theta_j-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)\right.$$
$$\left. + p_{i,j+1}^{-1}\mu'\left(\theta_{j+1}-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)\right]\mu'\left(\theta_j-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)\boldsymbol{x}_i,$$

$$\mathbb{E}\left[-\nabla_{\boldsymbol{\beta}}^2\ell_i(\theta,\boldsymbol{\beta})\right]$$
$$= \sum_{j=1}^{J}p_{ij}^{-1}\left[\mu'\left(\theta_j-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)-\mu'\left(\theta_{j-1}-\boldsymbol{x}_i^T\boldsymbol{\beta}\right)\right]^2\boldsymbol{x}_i\boldsymbol{x}_i^T.$$

We partition the FIM at the null model, that is, $\gamma_1=\cdots=\gamma_q=0$, as

and denote the score vector (gradient) with respect to $\boldsymbol{\gamma}$ at the null model as $\boldsymbol{R}$. To test significance of $\boldsymbol{\gamma}$, we calculate the score test statistic as

$$S=\boldsymbol{R}^T(\boldsymbol{Q}-\boldsymbol{W}^T\boldsymbol{P}^{-1}\boldsymbol{W})^{-1}\boldsymbol{R}$$

and compare to the Chi-square distribution with q degrees of freedom. $\boldsymbol{P}^{-1}$ is precomputed and, for each SNP or SNP-set, we only need to update $\boldsymbol{W}$ and $\boldsymbol{Q}$, which cost $O(q^3+nq^2)$ flops. Since q is typically small, the computation cost scales linearly with sample size, making it scalable to Biobank data with 10^5–10^6 samples and millions of SNPs.

2.3 | Software

We have developed a package using the high-performance dynamic programming language Julia (Bezanson, Edelman, Karpinski, & Shah, 2017) to perform GWAS analyses on single SNPs, SNP-sets, or $G\times E$ interactions (https://github.com/OpenMendel/OrdinalGWAS.jl) as part of the OpenMendel umbrella (Zhou et al., 2019). Users can run the software on Julia version 1.0 or later, or use Docker without installing Julia. Our package allows easy specification of the type of test (score or LRT), link function, covariates to include in the null model, masks for SNPs or samples, and formula for interactions. The package requires a covariate file, genotype data, and a formula for the null model. It outputs a text file in comma separated values (CSV) format with p values and relevant information for each SNP, including fitted effect size coefficients if the LRT option is specified, and another text file with the fitted null-model.

For large data sets, a practical strategy is to perform score tests first, then redo an LRT for the most promising SNPs according to score test p values. Running the score test allows very quick screening of significant SNPs compared with the LRT, which is especially advantageous for large data sets. As mentioned in this section, the two tests are asymptotically equivalent and when tested through simulations, the two tests yielded similar power even at a modest sample size of 2,500. It is recommended to screen SNPs using the score test if time and computational resources are limited, and then evaluate the LRT on SNPs that meet a threshold significant to the investigator to retrieve the LRT p value along with the estimated effect size. If the investigator needs effect size estimates of all SNPs or if computational resources and time are not important, then using the LRT for all SNPs will be preferable. The choice of link function may depend on several factors. The logit link function yields easily interpretable results and is widely used as it results in the proportional odds model, but the results can change based on the link function used. In our analyses, we use the link function that yields the highest loglikelihood for the null model.

3 | RESULTS

3.1 | Simulated data examples

To assess the adequacy of the ordered multinomial model in a GWAS setting, we performed Type I error and power comparisons between ordered multinomial regression

with logit link function, linear regression, logistic regression, and multinomial regression in a simulation setting. We generated covariates age and gender from Normal($\mu = 45$, $\sigma^2 = 64$) and Bernoulli($p_{male} = .51$) distributions, respectively. The effects of the gender and standardized age variables were set to 1.0 and 2.0, respectively. The genotype vector was generated according to Hardy–Weinberg Equilibrium (HWE) with varying minor allele frequencies (MAFs) between 5% and 20%. The response variable was generated using a proportional odds assumption from the simulated covariates, genotype vector, and effect sizes with a total of four ordered categories. For the logistic regression, we dichotomized the ordered response variable as $y_{logit} = 0$ if the ordinal variable was 1 or 2, and $y_{logit} = 1$ if the ordinal variable was 3 or 4.

The heterozygous ordered-log odds multiplicative effect size for each minor allele of the genotype vector, γ, was varied from the null value of 0–0.5. Different intercept values, θ, were also tested. We used 10^6 replicates for each null effect size scenario to evaluate the Type I error. We used 1,000 replicates at each nonzero effect size to test the power of the model. Sample size varied from 2,000 to 10,000. The p values of the ordered multinomial regression are derived from using the score test statistic. Results of different settings for Type I error are shown in Table 2 quantile-quantile (QQ) plots where $\theta = (0.1, 3.0, 3.1)$, MAF = 0.2, and the sample size was 5,000 are displayed in Figure 2. The p values for the logistic and multinomial regression show heavy tails, indicating overall significant (inflated) p values.

The results of our power analysis are displayed in Figure 3, where a significance level of 10^{-5} was used. We show that there are conditions, where the ordered multinomial model has distinctively higher power than other commonly used existing methods. When the underlying intercept values, θ, are disproportionately nonuniform (right panel of Figure 3), which can happen in a real-world setting, using logistic regression can have over 30% reduced power over the ordered multinomial regression. When θ is set to a more favorable scenario for logistic regression, there is less of a difference in power, but the ordered multinomial method still performs well, where the multinomial regression does less favorably.

In terms of power, the ordered multinomial method has several advantages. It does not assume linear spacing between ordinal categories, so it applies to real-world settings where the definition of ordered variables depends on several different measures. The ordered multinomial model also only needs to estimate one more parameter for each category added ($K - 2$ more parameters than binary logistic regression for K ordinal categories). In contrast the multinomial regression requires an additional set of all parameters for each additional category, which can result in overfitting and a loss in power. The use of logistic regression in ordinal data has been ad hoc. It is common to run several regressions on different grouping of cases and controls and then examine the overlap. Another approach is to omit the in-between categories, which reduces sample size and power. Using an ordered multinomial regression allows for much of the data to be used while maintaining a rather parsimonious model.

We detail power simulation results for $G \times E$ and SNP-set analysis in Supporting Information Section S.5. In summary, our results are similar to the single-SNP results in that there are highly plausible scenarios in which the ordinal multinomial model outperforms the common existing methods for both $G \times E$ and SNP-set analyses.

3.2 | COPDGene GWAS

We apply our method to COPDGene, a large case–control sample of well-characterized smokers from a GWAS

TABLE 2 Empirical Type I error rates ($\times 10^{-5}$) at significance level 10^{-5} based on 1,000,000 replicates

| n | MAF | $\theta = (1.0, 1.2, 1.4)$ | | | | $\theta = (0.1, 3.0, 3.1)$ | | | |
		Linear	Logistic	Multinomial	Ordinal	Linear	Logistic	Multinomial	Ordinal
2,000	0.05	1.2	1.0	1.2	1.0	1.0	0.8	0.5	1.0
	0.10	1.6	1.3	0.9	1.1	0.8	0.6	0.5	0.9
	0.20	0.7	0.7	1.0	0.8	1.8	0.5	0.6	1.4
5,000	0.05	0.8	0.6	1.5	0.5	1.4	0.5	0.6	1.3
	0.10	0.9	0.7	0.9	0.8	0.9	1.5	0.9	0.4
	0.20	1.0	0.9	1.2	0.8	0.6	1.0	0.5	1.2
10,000	0.05	0.6	0.3	1.0	0.4	1.5	1.4	1.7	1.4
	0.10	1.3	0.6	1.0	0.8	1.0	1.1	0.8	1.1
	0.20	0.8	0.9	1.3	0.9	1.3	1.1	1.0	0.6

Note: All standard errors for all estimated Type I errors are all smaller than 4.25×10^{-6}.
Abbreviation: MAF, minor allele frequency.

FIGURE 2 QQ plots of *p* values from Type I error simulation for $\theta = (0.1, 3.0, 3.1)$ at MAF = 0.2 and sample size $n = 5,000$. Regression type is displayed above each plot. MAF, minor allele frequency

of respiratory disease. Data were requested through NCBI's dbGAP repository under study accession: phs000179.v6.p2. It includes 10,192 non-Hispanic white (NHW) and African American (AA) current and former smokers with airflow obstruction ranging from none to GOLD Stage 4 (very severe) COPD. The study design of COPDGene has been reported previously (Regan et al., 2010). Briefly, the subjects are included between the ages of 45 and 80 with at least a 10 pack-year smoking history. Exclusion criteria include pregnancy, history of other lung disease except asthma, prior lobectomy or lung volume reduction surgery, active cancer undergoing

treatment, or known or suspected lung cancer. Because Lutz et al. (2015) analyzed AA and NHW separately, we applied our method to the larger of the two populations, the NHW population, which includes 6,678 individuals after data quality control and exclusions. Details concerning genotyping, quality control, and imputation are posted on the COPDGene website (http://www.copdgene.org). Variable *final gold* based on the GOLD's guidelines for classifying COPD was used. Summary statistics of the cohort are shown in Supporting Information Section S.1 and Table S1. Histograms of MAFs, missing SNPs per person, and missing people per

FIGURE 3 Continued.

SNP of the NHW COPDGene genotype data are shown in Figure S1.

We compare our method using the logit link function to the method previously used to analyze the data, logistic regression, and find that our ordinal regression method produces similar, and in some cases more significant results. After excluding data from the individuals with missing data (19 individuals), and those in the unclassifiable category (FEV1/FVC ratio ≥ 0.7 but predicted FEV1 $\leq 80\%$; 698 individuals), ordinal multinomial GWAS was run on data from a total of 5,953 individuals and 630,860 SNPs controlling for gender, age, pack years, height, and the first 10 principal components as was done in Lutz et al. (2015). For logistic regression, we ran the model using category 0 as controls and categories 2–4 as cases. The score test was used on all SNPs, with the LRT run for the top hits ($p < 10^{-6}$). Figure 4 presents the Manhattan plots of the results of the logistic and ordered multinomial GWAS. The ordered multinomial and logistic regressions produce similar results with peaks appearing on chromosome 15 ($p = 2.761 \times 10^{-11}$ for ordered multinomial and p value = 1.232×10^{-8} for logistic). The difference in the magnitude of the p values is quite impressive, with the more significant signal coming from the ordered multinomial regression. Ordered multinomial regression produces potential signals on chromosomes 3 and 4, whereas logistic regression produces a signal on chromosome 4 and but no clear sign of a potential signal on chromosome 3. The nearest gene to the SNP relating to the potential signal using ordered multinomial regression ($p = 5.731 \times 10^{-7}$) on chromosome 3 is *EEFSEC*, which has been shown to be associated with COPD (Hobbs et al., 2017). Locuszoom plot of association results, linkage disequilibrium, and recombination rates around the top hits can be found in Supporting Information Section S.2 and Figure S2.

Our implementation in OrdinalGWAS.jl is fast. GWAS analysis on a standard laptop running Mac OS with a quad-core processor took just under 3.5 min.

Under an extreme case, where we remove all individuals in the middle and only run the GWAS on individuals falling under *not a case* and *GOLD Stage 4*, we see a general trend that effect sizes are larger, but p values are less significant. Manhattan plot for this

analysis is in Figure S3. Here we see that using different criteria for binary variables can lead to different, and therefore less interpretable results. Since the cutoff point for generation of binary variables from ordinal ones is arbitrary, two analyses on the same data may yield different results. Although linear regression on ordinal variables leads to problems with interpretability, we ran linear regression GWAS on the COPDGene data and have included the Manhattan plot in Figure S4. Interestingly, but not completely unexpected when dealing with real data, the peak on chromosome 15 is slightly more significant with linear regression than with ordinal multinomial regression.

3.3 | Hypertension GWAS in UK Biobank

Hypertension is a heritable trait (Muñoz et al., 2016) and a modifiable driver of risk for stroke and coronary artery disease. It is a leading cause of global mortality and morbidity (GBD, 2015). GWAS meta-analyses and analyses of custom or exome content have identified and replicated genetic variants associated with elevated blood pressure (BP) and severe hypertension at over 120 loci (Warren et al., 2017). These researchers carefully construct a single quantitative measure of BP and find many associated loci, replicating previous findings and discovering new potential loci. However none of the existing studies looks at SNPs associated with hypertension as an ordinal trait due to the lack of computational tools for analyzing ordinal outcomes at Biobank scale. Here we demonstrate the ability of our software by applying it to the UK Biobank BP data set. The UK Biobank is a prospective cohort study of approximately 500,000 men and women aged 40–69 years with extensive baseline phenotypic measurements, stored biological samples and follow-up by EHR linkage (Sudlow et al., 2015). In this section, we report the association between five categories of hypertension (defined using 2017 Guidelines; Whelton et al., 2018) and genetic variants among participants in UK Biobank.

We define hypertensive phenotype based on 2017 Guidelines for the Prevention, Detection, Evaluation, and Management of High BP in Adults (Whelton et al., 2018).

FIGURE 3 These plots display the power of ordered multinomial, linear regression, logistic regression, and multinomial regression based on 1,000 replicates of generating data with four ordered categories from a proportional odds assumption with a sample size of $n = 5,000$ at a 10^{-5} significance level. Minor allele frequency (MAF) of the simulated causal variant ranges from 0.05 to 0.20, and intercept values for the simulated response variable are $\theta = (1.0, 1.2, 1.4)$ for the plot on the left and $\theta = (0.1, 3.0, 3.1)$ for the plot on the right. Effect sizes, γ, range from 0.0 to 0.5

**FIGURE 4** Manhattan plots for the COPD GWAS results in COPDGene. Left is the Manhattan plot using logistic regression. Right is the Manhattan plot using ordered multinomial regression. The blue line indicates the Bonferroni correction threshold. COPD, chronic obstructive pulmonary disease; GWAS, genome-wide association study

Normal: systolic BP (SBP)/diastolic BP (DBP) < 120/80 mm Hg;

Elevated: SBP between 120 and 129 mm Hg and DBP < 80 mm Hg;

Stage 1: SBP between 130 and 139 mm Hg or DBP between 80 and 89 mm Hg;

Stage 2: SBP at least 140 mm Hg or DBP at least 90 mm Hg;

Hypertensive crisis: SBP over 180 mm Hg and/or DBP over 120 mm Hg.

Our GWAS analysis is performed using data from the second release of UK Biobank participants. Individuals from UK Biobank were genotyped at ~800, 000 SNPs with a custom Affymetrix UK Biobank Axiom array. Nonimputed data were used in the analysis. Information on UK Biobank array design and protocols is available on the UK Biobank website. Following quality control procedures already carried out centrally by UK Biobank, we excluded samples with quality control failures, sex discordance, and high heterozygosity/missingness ($n = 968$). We further restricted our data to a subset of individuals of European ancestry and exclude first- and second-degree relatives using kinship data leading to the exclusion of data from another 150,832 individuals. This leads to a sample of $n = 337,545$ individuals. We filtered samples by 98% genotyping success rate on all chromosomes and SNPs by 99% genotyping success rate and an MAF of at least 2% over the whole population. These measures result in $n = 185,565$ individuals and 464,137 SNPs for analysis.

Baseline characteristic of 185,565 participants is shown in Supporting Information Section S.3 and Table S2. There are 34,009 (10.0%) participants who had undertaken hypertension-related medications at baseline. These people were excluded from the analysis. Five categories of hypertension were first defined by their SBP and DBP. The final set of individuals is distributed as 16% with normal BP, 13% with elevated BP, 27% in Stage 1 hypertension, 40% in Stage 2 hypertension, and 2% in

FIGURE 5 Manhattan plots for the hypertension GWAS results in UK Biobank. Left is the Manhattan plot using logistic regression. Right is the Manhattan plot using ordered multinomial regression. The blue line indicates the Bonferroni correction threshold. GWAS, genome-wide association study

hypertension crisis. We compare our method to GWAS using logistic regression, defining hypertension cases as belonging to Stage 2 or higher as done in Warren et al. (2017). We recalculated principal components using FlashPCA after filtering individuals and SNPs through quality control (QC) filters, because the subset of individuals we analyze is exclusively of British ancestry, and the original principal components were calculated before filtering (Abraham, Qiu, & Inouye, 2017). Our hypertension GWAS analysis includes the following covariates: sex, center, age, age^2, body mass index (BMI), and the top 10 principal components to adjust for ancestry/relatedness. We used the logit link function for the ordered multinomial GWAS as it yielded the highest loglikelihood for the null model. The score test was used on all SNPs, with the LRT run for the top hits ($p < 10^{-8}$). The Manhattan plots are displayed in Figure 5 and the QQ plots in Figure S5. Information on the top hits from OrdinalGWAS on the UK Biobank data is included in the Supporting Information excel table. The genomic inflation factor from OrdinalGWAS is 1.252, a high, but expected value for polygenic traits like BP in a GWAS that includes a large sample size and many SNPs in high linkage disequilibrium (LD) (Evangelou et al., 2018). The analysis took 181 min to run on a standard laptop with a quad-core processor running on Mac OS.

The use of logistic regression on the binary hypertension variable yielded hits at similar locations, with less significance. The genomic inflation factor was similarly high at 1.173. As in the case of our COPD analysis, the logistic and ordinal multinomial regression analyses gave qualitatively similar results with, in general, the ordinal multinomial regression providing more power than the ordinal regression. Overall our results are consistent with the polygenic nature of BP with log odds ratios of significant hits ranging between −0.0773 and 0.1107. In general, rare variants tended to have higher effect sizes than common variants.

We also performed SNP-set and $G \times E$ analysis to demonstrate our software's capability to do so on the UK Biobank data. $G \times E$ was run with sex as the environmental variable on the SNPs that passed ($p < 10^{-8}$) from the original analysis. Results of this analysis are found in Table S4. The Manhattan plot for the SNP-set analysis with a window size of 20 SNPs is in Figure S6.

4 | DISCUSSION

We have developed a method tailored to GWAS on ordinal traits. In many instances, it increases power and allows for a more simplified setup and interpretation than existing approaches, since cutpoints for transforming ordinal traits into binary traits are usually arbitrary and not agreed upon. The strategy of conducting a score test on each SNP and then only running an LRT on the top SNPs allows our method to scale to Biobank scale GWAS data sets.

We have shown that the model has appropriate Type I error when looking at various sample sizes and MAFs, while logistic and multinomial regression can result in inflated Type I error under certain conditions. We have shown situations where using ordered multinomial regression can lead to significant power gains over logistic regression when the specification of the logistic case/control response variable is poor. Our framework will be most useful in finding causal loci related to complex diseases that have no clear distinction between what constitutes a case versus a control, but where disease progression can be well specified.

Besides single-SNP GWAS, our software also implements GWAS for SNP-sets and $G \times E$ interactions. This allows for many more types of GWAS to be performed with ordinal outcomes and covers much of the current existing needs.

Other models that relax the proportional odds assumption may be useful to explore. These models, such as a partial proportional odds model (Peterson & Harrell, 1990), allow for some covariates to violate the proportional odds assumption, but they lead to less parsimonious models and less interpretable results since a separate effect size and p value is produced for each group of ordered outcomes.

For the COPDGene data, our method had a much stronger signal than logistic regression on chromosome 15. Ordered multinomial regression had a suggestive signal on chromosome 3 that has been associated with COPD from another study, but missed by the logistic regression. Although we did not recover the Bonferroni-corrected signal that logistic regression did in the COPDGene data, the signal on the SNP was still suggestive and the lowest p value above the threshold. We suspect the lower p value could be due to the fact that the SNP heavily violated the proportional odds assumption. However, it is difficult to verify this. Current tests for the proportional odds assumption have been described as very liberal, often leading to rejection when there are many parameters in the model or the sample size is large (Allison, 1999).

Our software scales to Biobank data with hundreds of thousands of individuals genotyped at hundreds of thousands of SNPs. Our goal in analyzing the UK Biobank BP data was not to report new findings for hypertension, but to demonstrate the scalability of our method and to show how the results of ordinal multinomial regression differ from those of a standard logistic regression analysis. When applied to the UK Biobank

data, signals were generally substantially stronger than those from logistic regression on the binary hypertension variable using the same individuals in both analyses. Comparison to other analyses of the UK Biobank BP data is not straightforward and we do not recommend it. There are a number of ways of our treatment of the data that deviate from previous studies besides treating the outcomes as ordered categories (Evangelou et al., 2018; Warren et al., 2017). We used nonimputed, hard genotype calls, whereas other studies used imputed fractional dosage data. By not using imputation we analyzed far fewer markers and excluded more individuals. We used genotype and phenotype data on 185,565 individuals of British ancestry, whereas other studies used genotype and phenotype data on individuals with European ancestry. We excluded individuals who took BP medications, whereas other studies adjusted for medication use. Our results use only UK Biobank data, whereas other studies report results of meta-analyses. It is thus not surprising that our results differ from previous BP trait GWAS with UK Biobank. Still, even with all the caveats, a large number of the loci, notably CACNB2, MTHFR, and PLCD3, have been reported to be linked to hypertension in previous studies (Levy et al., 2009; Newton-Cheh et al., 2009; Thomsen et al., 2017).

In summary, we have developed an ordinal multinomial regression approach for GWAS of hundreds of thousands of individuals. The method has similar computational requirements as score tests for logistic regression but it is more powerful for analyzing ordinal data. Our software is easy to use and freely available at https://github.com/OpenMendel/OrdinalGWAS.jl as part of the OpenMendel ecosystem (Lange et al., 2013; Zhou et al., 2019).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from NCB's dbGaP and UK Biobank repositories. The COPDGene study is under study accession: phs000179.v6.p2. The UK Biobank data are retrieved under Project ID: 48152 and 15678. Data are available at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000179.v6.p2 and https://www.ukbiobank.ac.uk with the permission of NCBI and UK Biobank.

ORCID

Jin J. Zhou http://orcid.org/0000-0001-7983-0274

REFERENCES

Abraham, G., Qiu, Y., & Inouye, M. (2017). FlashPCA2: Principal component analysis of Biobank-scale genotype datasets. *Bioinformatics*, *33*, 2776–2778. https://doi.org/10.1093/bioinformatics/btx299

Agresti, A. (2010). *Analysis of ordinal categorical data* (2nd ed.). Hoboken, NJ: John Wiley & Sons Inc. https://doi.org/10.1002/9780470594001

Agresti, A. (2018). *An introduction to categorical data analysis*. New Jersey: Wiley.

Allison, P. D. (1999). *Logistic regression using the SAS system: Theory and application*. Cary, NC: SAS Institute Corp.

Bezanson, J., Edelman, A., Karpinski, S., & Shah, V. B. (2017). Julia: A fresh approach to numerical computing. *SIAM Review*, *59*, 65–98. https://doi.org/10.1137/141000671

Developing statistical methods and computational algorithms for identifying biomarkers at Biobank-data scale for cardiometabolic traits (UK Biobank Project ID: 48152). (2019).

Genetic basis of circulating biomarkers, cardiometabolic disease, body composition and lifestyle (UK Biobank Project ID: 5678). (2019).

Genetic epidemiology of COPD (COPDGene). NCBI dbGaP study session ID: phs000179.v6.p2. (2019).

Eastwood, S. V., Mathur, R., Atkinson, M., Brophy, S., Sudlow, C., Flaig, R., ... Chaturvedi, N. (2016). Algorithms for the capture and adjudication of prevalent and incident diabetes in UK Biobank. *PLOS ONE*, *11*, 1–18. https://doi.org/10.1371/journal.pone.0162388

Evangelou, E., Warren, H. R., Mosen-Ansorena, D., Mifsud, B., Pazoki, R., Gao, H., ... Million Veteran Program. (2018). Genetic analysis of over 1 million people identifies 535 new loci

associated with blood pressure traits. *Nature Genetics*, *50*, 1412–1425. https://doi.org/10.1038/s41588-018-0205-x

Gaziano, J. M., Concato, J., Brophy, M., Fiore, L., Pyarajan, S., Breeling, J., ... O'Leary, T. J. (2016). Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *Journal of Clinical Epidemiology*, *70*, 214–223. https://doi.org/10.1016/j.jclinepi.2015.09.016

GBD 2015 Risk Factors Collaborators. (2015). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: A systematic analysis for the global burden of disease study 2015. *Lancet (London, England)*, *388*, 1659–1724. https://doi.org/10.1016/S0140-6736(16)31679-8

Hobbs, B. D., de Jong, K., Lamontagne, M., Bossé, Y., Shrine, N., Artigas, M. S., ... International COPD Genetics Consortium. (2017). Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. *Nature Genetics*, *49*, 426. https://doi.org/10.1038/ng.3752

Lange, K., Papp, J., Sinsheimer, J., Sripracha, R., Zhou, H., & Sobel, E. (2013). Mendel: The Swiss army knife of genetic analysis programs. *Bioinformatics*, *29*, 1568–1570.

Levy, D., Ehret, G. B., Rice, K., Verwoert, G. C., Launer, L. J., Dehghan, A., ... van Duijn, C. M. (2009). Genome-wide association study of blood pressure and hypertension. *Nature Genetics*, *41*, 677–687. https://doi.org/10.1038/ng.384

Lutz, S. M., Cho, M. H., Young, K., Hersh, C. P., Castaldi, P. J., McDonald, M.-L., ... ECLIPSE Investigators, and COPDGene Investigators. (2015). A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. *BMC Genetics*, *16*, 138. https://doi.org/10.1186/s12863-015-0299-4

Morris, A. P., Lindgren, C. M., Zeggini, E., Timpson, N. J., Frayling, T. M., Hattersley, A. T., & McCarthy, M. I. (2010). A powerful approach to sub-phenotype analysis in population-based genetic association studies. *Genetic Epidemiology*, *34*, 335–343. https://doi.org/10.1002/gepi.v34:4

Muñoz, M., Pong-Wong, R., Canela-Xandri, O., Rawlik, K., Haley, C. S., & Tenesa, A. (2016). Evaluating the contribution of genetics and familial shared environment to common disease using the UK Biobank. *Nature Genetics*, *48*, 980. https://doi.org/10.1038/ng.3618

Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L., ... Munroe, P. B. (2009). Genome-wide association study identifies eight loci associated with blood pressure. *Nature Genetics*, *41*, 666–676. https://doi.org/10.1038/ng.361

O'Reilly, P. F., Hoggart, C. J., Pomyen, Y., Calboli, F. C. F., Elliott, P., Jarvelin, M.-R., ... Coin, L. J. M. (2012). MultiPhen: Joint model of multiple phenotypes can increase discovery in GWAS. *PLOS ONE*, *7*, 1. https://doi.org/10.1371/journal.pone.0034861

Peterson, B., & Harrell, F. E. (1990). Partial proportional odds models for ordinal response variables. *Journal of the Royal Statistical Society. Series C (Applied Statistics)*, *39*, 205–217. https://doi.org/10.2307/2347760

Regan, E. A., Hokanson, J. E., Murphy, J. R., Make, B., Lynch, D. A., Beaty, T. H., ... Crapo, J. D. (2010). Genetic epidemiology of COPD (COPDGene) study design. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, *7*, 32–43. https://doi.org/10.3109/15412550903499522

Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., ... Collins, R. (2015). UK Biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLOS Medicine*, *12*, e1001779. https://doi.org/10.1371/journal.pmed.1001779

Thomsen, L. C. V., McCarthy, N. S., Melton, P. E., Cadby, G., Austgulen, R., Nygård, O. K., ... Iversen, A.-C. (2017). The antihypertensive MTHFR gene polymorphism rs17367504-G is a possible novel protective locus for preeclampsia. *Journal of Hypertension*, *35*, 132–139. https://doi.org/10.1097/HJH.0000000000001131

Vestbo, J., Hurd, S. S., Agust, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., ... Rodriguez-Roisin, R. (2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, *187*, 347–365. https://doi.org/10.1164/rccm.201204-0596PP

Visscher, P. M., Wray, N. R., Zhang, Q., Sklar, P., McCarthy, M. I., Brown, M. A., & Yang, J. (2017). 10 Years of GWAS discovery: Biology, function, and translation. *The American Journal of Human Genetics*, *101*, 5–22. https://doi.org/10.1016/j.ajhg.2017.06.005

Wan, E. S., Hokanson, J. E., Murphy, J. R., Regan, E. A., Make, B. J., Lynch, D. A., ... COPDGene Investigators. (2011). Clinical and radiographic predictors of gold-unclassified smokers in the copdgene study. *American Journal of Respiratory and Critical Care Medicine*, *184*, 57–63. https://doi.org/10.1164/rccm.201101-0021OC

Wang, K. (2014). Testing genetic association by regressing genotype over multiple phenotypes. *PLOS ONE*, *9*, 1–9. https://doi.org/10.1371/journal.pone.0106918

Warren, H. R., Evangelou, E., Cabrera, C. P., Gao, H., Ren, M., Mifsud, B., ... UK Biobank CardioMetabolic Consortium BP Working Group. (2017). Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. *Nature Genetics*, *49*, 403–415. https://doi.org/10.1038/ng.3768

Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., ... Wright, J. T. (2018). 2017 acc/aha/aapa/abc/acpm/ags/apha/ash/aspc/nma/pcna guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. *Journal of the American College of Cardiology*, *71*, e127–e248. https://doi.org/10.1016/j.jacc.2017.11.005

Zhou, H., Sinsheimer, J. S., Bates, D. M., Chu, B. B., German, C. A., Ji, S. S., ... Lange, K. (2019). OpenMendel: A cooperative programming project for statistical genetics. *Human Genetics*, https://doi.org/10.1007/s00439-019-02001-z. Advanced online publication.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information section.